<DOC>
	<DOCNO>NCT00401024</DOCNO>
	<brief_summary>RATIONALE : Collecting sample tumor tissue blood patient cancer study laboratory may help doctor learn patient respond treatment . PURPOSE : This clinical trial look tumor tissue sample patient receive imatinib mesylate malignant glioma see much imatinib mesylate find tumor tissue .</brief_summary>
	<brief_title>Tumor Tissue Analysis Patients Receiving Imatinib Mesylate Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy , imatinib mesylate , term achieve therapeutic tumor : plasma concentration ratio , patient primary malignant glioma . Secondary - Correlate tumor grade ( low vs high ) and/or tumor enhancement MRI tumor concentration drug patients. , OUTLINE : Patients receive oral imatinib mesylate daily 7-12 day . Patients undergo surgical resection . Blood tissue sample collect time surgery analyze imatinib mesylate concentration . After completion study treatment , patient follow 7 day . PROJECTED ACCRUAL : A total 33 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma 1 follow subtypes : Lowgrade glioma Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Unifocal disease progressive recurrent prior radiotherapy and/or chemotherapy Scheduled undergo surgical resection Able undergo maximal surgical resection tumor mass PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Mini Mental Status Exam ≥ 15 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≥ 1.7 mg/dL BUN ≤ 2 time upper limit normal ( ULN ) Transaminases ≤ 4 time ULN Not pregnant nursing Fertile patient must use effective contraception ≥ 1 month completion study treatment No medical illness would preclude study treatment , include follow : Serious infection Uncontrolled hypertension Unstable angina pectoris Uncontrolled cardiac dysrhythmia PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 4 week since prior investigational drug No 1 prior chemotherapy regimen No concurrent chemotherapy , biologic therapy , radiotherapy No concurrent medication may interact imatinib mesylate interfere hepatic cytochrome P450 system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
</DOC>